vs
Revvity（RVTY）与SouthState Bank Corp（SSB）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是SouthState Bank Corp的1.2倍（$772.1M vs $661.7M），SouthState Bank Corp净利率更高（34.1% vs 12.7%，领先21.4%），过去两年SouthState Bank Corp的营收复合增速更高（37.4% vs 9.0%）
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
SouthState Bank总部位于美国佛罗里达州温特黑文，是银行控股公司SouthState Corporation旗下的银行子公司。截至2025年5月26日，该行已在南卡罗来纳、北卡罗来纳、佐治亚、佛罗里达、阿拉巴马、弗吉尼亚、科罗拉多、得克萨斯八州设有371家营业网点，为当地客户提供各类银行金融服务。
RVTY vs SSB — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$661.7M
净利率更高
SSB
高出21.4%
12.7%
两年增速更快
SSB
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $772.1M | $661.7M |
| 净利润 | $98.4M | $225.8M |
| 毛利率 | — | — |
| 营业利润率 | 14.5% | 15.1% |
| 净利率 | 12.7% | 34.1% |
| 营收同比 | 5.9% | — |
| 净利润同比 | 3.9% | 153.5% |
| 每股收益（稀释后） | $0.86 | $2.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RVTYSSB
| Q1 26 | — | $661.7M | ||
| Q4 25 | $772.1M | $581.1M | ||
| Q3 25 | $698.9M | $599.7M | ||
| Q2 25 | $720.3M | $577.9M | ||
| Q1 25 | $664.8M | $544.5M | ||
| Q4 24 | $729.4M | $369.8M | ||
| Q3 24 | $684.0M | $351.5M | ||
| Q2 24 | $691.7M | $350.3M |
净利润RVTYSSB
| Q1 26 | — | $225.8M | ||
| Q4 25 | $98.4M | $247.7M | ||
| Q3 25 | $46.7M | $246.6M | ||
| Q2 25 | $53.9M | $215.2M | ||
| Q1 25 | $42.2M | $89.1M | ||
| Q4 24 | $94.6M | $144.2M | ||
| Q3 24 | $94.4M | $143.2M | ||
| Q2 24 | $55.4M | $132.4M |
毛利率RVTYSSB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 53.6% | — | ||
| Q2 25 | 54.5% | — | ||
| Q1 25 | 56.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 55.7% | — |
营业利润率RVTYSSB
| Q1 26 | — | 15.1% | ||
| Q4 25 | 14.5% | 54.3% | ||
| Q3 25 | 11.7% | 53.6% | ||
| Q2 25 | 12.6% | 48.8% | ||
| Q1 25 | 10.9% | 22.3% | ||
| Q4 24 | 16.3% | 50.7% | ||
| Q3 24 | 14.3% | 53.1% | ||
| Q2 24 | 12.4% | 49.3% |
净利率RVTYSSB
| Q1 26 | — | 34.1% | ||
| Q4 25 | 12.7% | 42.6% | ||
| Q3 25 | 6.7% | 41.1% | ||
| Q2 25 | 7.5% | 37.2% | ||
| Q1 25 | 6.4% | 16.4% | ||
| Q4 24 | 13.0% | 39.0% | ||
| Q3 24 | 13.8% | 40.7% | ||
| Q2 24 | 8.0% | 37.8% |
每股收益（稀释后）RVTYSSB
| Q1 26 | — | $2.28 | ||
| Q4 25 | $0.86 | $2.47 | ||
| Q3 25 | $0.40 | $2.42 | ||
| Q2 25 | $0.46 | $2.11 | ||
| Q1 25 | $0.35 | $0.87 | ||
| Q4 24 | $0.77 | $1.88 | ||
| Q3 24 | $0.77 | $1.86 | ||
| Q2 24 | $0.45 | $1.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $919.9M | $2.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.3B | $9.0B |
| 总资产 | $12.2B | $68.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RVTYSSB
| Q1 26 | — | $2.9B | ||
| Q4 25 | $919.9M | — | ||
| Q3 25 | $931.4M | — | ||
| Q2 25 | $991.8M | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $2.0B | — |
股东权益RVTYSSB
| Q1 26 | — | $9.0B | ||
| Q4 25 | $7.3B | $9.1B | ||
| Q3 25 | $7.4B | $9.0B | ||
| Q2 25 | $7.6B | $8.8B | ||
| Q1 25 | $7.6B | $8.6B | ||
| Q4 24 | $7.7B | $5.9B | ||
| Q3 24 | $7.9B | $5.9B | ||
| Q2 24 | $7.9B | $5.7B |
总资产RVTYSSB
| Q1 26 | — | $68.0B | ||
| Q4 25 | $12.2B | $67.2B | ||
| Q3 25 | $12.1B | $66.0B | ||
| Q2 25 | $12.4B | $65.9B | ||
| Q1 25 | $12.4B | $65.1B | ||
| Q4 24 | $12.4B | $46.4B | ||
| Q3 24 | $12.8B | $46.1B | ||
| Q2 24 | $13.4B | $45.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $182.0M | — |
| 自由现金流经营现金流 - 资本支出 | $161.8M | — |
| 自由现金流率自由现金流/营收 | 21.0% | — |
| 资本支出强度资本支出/营收 | 2.6% | — |
| 现金转化率经营现金流/净利润 | 1.85× | — |
| 过去12个月自由现金流最近4个季度 | $509.4M | — |
8季度趋势，按日历期对齐
经营现金流RVTYSSB
| Q1 26 | — | — | ||
| Q4 25 | $182.0M | $232.1M | ||
| Q3 25 | $138.5M | $122.4M | ||
| Q2 25 | $134.3M | $72.6M | ||
| Q1 25 | $128.2M | $-126.3M | ||
| Q4 24 | $174.2M | $354.3M | ||
| Q3 24 | $147.9M | $-246.8M | ||
| Q2 24 | $158.6M | $126.8M |
自由现金流RVTYSSB
| Q1 26 | — | — | ||
| Q4 25 | $161.8M | $215.5M | ||
| Q3 25 | $120.0M | $101.7M | ||
| Q2 25 | $115.5M | $52.5M | ||
| Q1 25 | $112.2M | $-139.1M | ||
| Q4 24 | $149.8M | $340.9M | ||
| Q3 24 | $125.6M | $-254.2M | ||
| Q2 24 | $136.6M | $117.3M |
自由现金流率RVTYSSB
| Q1 26 | — | — | ||
| Q4 25 | 21.0% | 37.1% | ||
| Q3 25 | 17.2% | 17.0% | ||
| Q2 25 | 16.0% | 9.1% | ||
| Q1 25 | 16.9% | -25.5% | ||
| Q4 24 | 20.5% | 92.2% | ||
| Q3 24 | 18.4% | -72.3% | ||
| Q2 24 | 19.7% | 33.5% |
资本支出强度RVTYSSB
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 2.9% | ||
| Q3 25 | 2.6% | 3.5% | ||
| Q2 25 | 2.6% | 3.5% | ||
| Q1 25 | 2.4% | 2.4% | ||
| Q4 24 | 3.4% | 3.6% | ||
| Q3 24 | 3.3% | 2.1% | ||
| Q2 24 | 3.2% | 2.7% |
现金转化率RVTYSSB
| Q1 26 | — | — | ||
| Q4 25 | 1.85× | 0.94× | ||
| Q3 25 | 2.97× | 0.50× | ||
| Q2 25 | 2.49× | 0.34× | ||
| Q1 25 | 3.03× | -1.42× | ||
| Q4 24 | 1.84× | 2.46× | ||
| Q3 24 | 1.57× | -1.72× | ||
| Q2 24 | 2.87× | 0.96× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
SSB
| Net Interest Income | $561.6M | 85% |
| Noninterest Income | $100.1M | 15% |
